ARTA
AIM

A.R.T. Advisors’s AIM ImmunoTech AIM Stock Holding History

A.R.T. Advisors’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-124
Closed -$9K – 1938
2019
Q3 		$9K Buy
124
+24
+24% +$5.81K ﹤0.01% 1386
2019
Q2 		$44K Buy
+100
New +$60.5K ﹤0.01% 1256

Other funds holding AIM

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

A.R.T. Advisors's AIM Position: Q4 2019 in Review

A.R.T. Advisors sold out of AIM ImmunoTech (AIM) in Q4 2019, closing a stake of 124 shares — an estimated $9K sold.

A.R.T. Advisors first reported a position in AIM in Q2 2019 and held it in 2 quarters. The position peaked at $44K in Q2 2019. 9 funds tracked by Wall St. Rank hold AIM as of Q4 2019.

  • A.R.T. Advisors reported no remaining AIM ImmunoTech position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 124 AIM ImmunoTech shares in Q4 2019, an estimated $9K.
  • A.R.T. Advisors first reported a position in AIM ImmunoTech in Q2 2019 and held it in 2 quarters.
  • A.R.T. Advisors's AIM ImmunoTech position peaked at $44K in Q2 2019.
  • 9 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.